$2.20 has been breached

I thought indications from the AGM were that there would be support at this level. The chart looks very scarey at the moment. If it goes under $2.15 it'll look even worse. Long term probably still a good company, but traditionally biotechs struggle at the late stages of trying to get the product to market as the shareholders have unrealistic expectations of how quickly a new product/drug will be accepted by doctors, etc. It is often much slower than what they believe it will be. Sitting on the sidelines until the sentiment changes